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90. Results from random effect models were consistent with fixed effect models.
CONCLUSIONS: Based on this network meta-analysis, a significantly greater pro-
portion of patients with plaque psoriasis are expected to achieve a PASI 75 or PASI
90 response when treated with infliximab 5 mg/kg than with ustekinumab 45 mg or
ustekinumab 90 mg.
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OBJECTIVES: A systematic review of chronic non-malignant pain treatment with
tapentadol and strong opioids.METHODS: Thirteen electronic databases and other
sources were searched until November 2010 for relevant RCTs in chronic moderate/
severe pain investigating at least one WHO step 3 opioid. Two separate analyses
were performed, one for trials reporting the outcome in patients with severe pain,
the other including both moderate and severe pain conditions. Indirect compari-
sons were performed based on a network analysis. Trials with an enriched or an
enriched withdrawal design were excluded. Primary (pain intensity) and a number
of secondary endpoints were evaluated, including pain relief (30% and 50%), patient
global impression of change, quality-of-life, quality-of-sleep, discontinuations,
and selected adverse events. RESULTS: Only 10 trials were eligible for analysis of
patients with severe pain (8 investigating tapentadol and 2 trials comparing bu-
prenorphine patch (TDB) vs placebo). For moderate/severe pain, 42 relevant trials
were identified and indirect comparisons with TDB, transdermal fentanyl (TDF),
hydromorphone, morphine, and oxymorphone were performed. Tapentadol
showed statistically favourable results over oxycodone for pain intensity, 30% and
50% pain relief, patient global impression of change, and quality-of-life. Some of
the most important adverse events of chronic opioid treatment were significantly
less frequent with tapentadol as compared to oxycodone i.e. constipation, nausea,
and vomiting; discontinuations due to these adverse events were found signifi-
cantly reduced with tapentadol. Similar results were obtained for the network
analysis, i.e. tapentadol was superior for the primary outcome (pain intensity) to
hydromorphone and morphine, whereas fentanyl and oxymorphone showed
trends in favour of these treatments. Significantly less frequent gastrointestinal
adverse events were observed using tapentadol in comparison with fentanyl, hy-
dromorphone, morphine, and oxymorphone, apparently leading to significantly
reduced treatment discontinuations (for any reason). CONCLUSIONS: The benefit
risk ratio of tapentadol appears to be better compared to other step 3 opioids.
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OBJECTIVES: With previous estimates dating back to 1996-1997, new estimates of
incidence and prevalence are needed to accurately assess the current burden of
psoriasis in the UK. We examined incidence and prevalence in the UK primary care
setting using data from 2008 and 2009. METHODS: THIN, an electronic database
recently validated to study psoriasis in a population-based setting, was used. For
incidence, newly diagnosed patients aged 18 were identified by a psoriasis diag-
nosis (“Read Code”) in medical records between January 1, 2008 and December 31,
2008. For prevalence, a cross-section of patients aged 18 on July 1, 2009 were
selected who had received a psoriasis Read Code in their medical history. Total
person time for 2008 and mid-year patient counts for 2009 were provided as de-
nominators to calculate incidence and prevalence, respectively. Age and sex-spe-
cific rates were calculated and standardized to the UK 2008/2009 population,
respectively. RESULTS: The standardized incidence rate of adult psoriasis in 2008
was 28 (95% CI: 28-29) per 10,000 person-years and highest in 60-69 year olds at 34
(95% CI: 31-36) per 10,000 person-years. Psoriasis prevalence at 01July2009 was
2.83% (95% CI: 2.81-2.86) and highest in 70-79 year olds at 3.49% (95% CI: 3.42-3.56).
Overall, incidence did not vary by sex. However, prevalence in females under 40 was
significantly higher than in males of the same age group: 2.69% (95%CI: 2.65-2.73) vs.
2.42% (95%CI: 2.37-2.44). CONCLUSIONS: Incidence of psoriasis was higher than
rates previously reported in the UK. The high prevalence estimates reported in this
primary care database confirm findings from other European countries and indi-
cate that psoriasis is a condition for which medical attention is commonly sought
and that psoriasis represents a significant burden on the UK healthcare system.
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OBJECTIVES: To estimate the Budget Impact of Bendamustine introduction as a
treatment option for Multiple Myeloma (MM) patients, non-candidates for trans-
plantation, who are likely to be treated with high priced citostatic combinations.
METHODS: A Budget Impact model assuming a prevalent treatable population of
4826 patients with MM, with an incremental rate of 3% per year. The time horizon
considered was three years and the analysis was made from the perspective of the
Spanish Health System. Nine treatment cycles were considered for all the drug
regimens and for the treatment lines included (3 or more). Pharmaceutical expen-
diture on citostatic agents was analyzed, excluding other medical costs. The drug
costs were based on the official ex-factory prices (EFP), discounting the price reduc-
tion recently established by the Spanish Government. The base case scenario was
based on prevalent epidemiological, market research data available and experts
opinion input. The bendamustine scenario considered different drug combinations
and different dosages (90-120mg/m2), depending on the treatment line to analyze.
RESULTS: The drug expenditure for MM treatment is slightly under €120 Mio/year
in Spain. The single cycle costs range from €3 (MelphalanPrednisone) to €5969
(LenalidomideDexamethasone). Bendamustine based treatments would reach
7% to 21% of the treated patients from the first to the last year analyzed. Fifty-four
percent of the Bendamustine treatments considered were combinations with other
expensive drugs (Bortezomib or Thalidomide), where the Bendamustine cost was
only 17% or 21% respectively of the whole treatment regimen. The introduction of
Bendamustine would reduce drug expenditure in €6.6 Mio during the 3 years con-
sidered, expressed in €2011. CONCLUSIONS: The introduction of Bendamustine
would produce drug cost savings in the MM patients, mainly from the 2nd treat-
ment lines onwards. The savings observed in the model were mainly due to the
substitution of high cost combinations like those based on Bortezomib, Thalido-
mide or Lenalidomide therapies.
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OBJECTIVES: Qutenza® is a novel method of action for the treatment of patients
with peripheral neuropathic pain. Therefore it is important to assess the economic
impact of introducing Qutenza® in the Spanish market for the treatment of neuro-
pathic pain in adult patients. METHODS: A budget impact model was developed
using published data on disease prevalence and treatment, population growth,
drug tariffs, health care resource utilization, unit costs and market shares forecasts
for Spain. The perspective of the Spanish national health care system was chosen,
using a 5-year time horizon. Treatments analyzed in this study were carbamaz-
epine, capsaicin cream, pregabalin, lidocaine, duloxetine, amitriptyline, gabapen-
tin and Qutenza®. Costs considered included drug costs, physician visits, diagnos-
tic tests, hospitalisation and complementary non-pharmacological treatment. All
costs referred to EUR 2010. Direct medical annual costs per patient for each treat-
ment were estimated before and after the introduction of Qutenza® in order to
estimate the total annual healthcare costs.RESULTS:Based upon the Spanish adult
population data, the diagnosed population for 2010 suffering from neuropathic
pain was estimated at 235,480 adult patients of whom 217,819 were assumed to
receive treatment for their disease. Increases in the diagnosed and treated popu-
lation were expected with estimates of 236,224 and 218,507 patients in 2015, re-
spectively. Total health care costs over the next 5 years were estimated at €2695
million. Qutenza® was estimated to grow from 1.6% in the first year up to 5.6% in
the fifth year. Under these conditions, total healthcare costs were estimated at
€2,679 million. Mean annual costs per patient before the introduction of Qutenza®
were estimated at €2,059 and at €2,046 after its introduction. CONCLUSIONS: The
introduction of Qutenza® is likely to decrease the budget impact of neuropathic
pain treatments for the Spanish national health care system. Overall savings in the
economic burden of €16.7 million were found over the next 5 years.
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OBJECTIVES: Wegener’s granulomatosis (WG) is a rare disease, fatal without ther-
apy. Cyclophosphamide (CYC) administered by oral or intravenous route is the gold
standard. Intravenous CYC (IVCYC) is the reference in France. However, rituximab,
mainly used for treating B-cell lymphomas, is being tested in clinical trials for
treating WG. To estimate the economic impact of using rituximab to induce remis-
sion in WG patients. METHODS: The six months induction treatment cost was
evaluated for treating a hypothetical cohort of prevalent cases constituted by
newly diagnosed and relapsing cases. In France, WG prevalence was estimated at
about 3 per 100 000 inhabitants. Treatment cost included costs of hospital stays,
drugs, follow-up and therapeutic acts. The costs over five years were estimated by
a model which take into account efficacy data of each treatment (rates of remis-
sion, failure and infectious complications) and the proportion of patients treated
each year. Scenarios (S) were tested on hypothetical rituximab indications: pre-
scribed to 10% of newly diagnosed patients and 50% of relapsing patients in S1 and
100% of relapsing patients in S2. RESULTS: The number of prevalent cases was
estimated to be about 1,884 in France in 2010. Treatment of these cases with the
reference strategy using IVCYC costed 166 millions € over 5 years. The introduction
of rituximab in WG therapies induced an overcost of 900 K€ in S1 and 2 millions € in
S2 over 5 years. CONCLUSIONS: In our analysis which is not exhaustive, others
treatments used to induce remission were not evaluated. Results revealed that
rituximab should possibly be indicated when cyclophosphamide is contra-indi-
cated and when patients are refractory to previous treatments. Efficacy data of
rituximab use in long term (remission, relapses and complications induced) are
expected. Results of rituximab efficacy evaluated as a maintenance therapy are
also expected.
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